Advertisement


Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Advertisement